NTLA Stock Analysis: Buy, Sell, or Hold?
NTLA - Intellia Therapeutics, Inc
$12.84
0.40 (3.22%)
▲
5d:
+7.81%
30d:
+15.68%
90d:
+3.8%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Aug 20, 2026 at $12.70 · last confirmed Aug 21, 2026
Strength: 7.0/10
Get Alerted When NTLA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NTLA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NTLA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NTLA is currently trading at $12.84, which is considered extended relative to its 30-day fair value range of $10.88 to $12.48.
Technical Outlook: Technically, NTLA is in a downtrend. Immediate support is located at $11.41, while resistance sits at $13.35. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: NTLA scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $23.94 (+86.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NTLA is in a downtrend. Immediate support is located at $11.41, while resistance sits at $13.35. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: NTLA scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $23.94 (+86.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$10.88 -
$12.48
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
31.6%
Protect Your Profits
Holding NTLA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (13/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading 86.5% below Wall St target ($23.94)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.88 -
$12.48
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$11.41
Resistance Level
$13.35
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.93
Wall Street Target
$23.94
(+86.5%)
Revenue Growth (YoY)
-46.2%
Share & Embed Analysis
Last updated: August 22, 2026 4:26 PM ET
Data refreshes hourly during market hours. Next update: 5:26 PM
Data refreshes hourly during market hours. Next update: 5:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NTLA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$109 | 66 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
Advanced NTLA Option Strategies
Professional options setups generated by AI based on today's NTLA price and gamma walls.
